Search Results

You are looking at 121 - 130 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Chronic Lymphocytic Leukemia: Individualizing Treatment Approach

Andrew D. Zelenetz

(PFS) and complete response (CR) rate. However, BR was associated with lower rates of neutropenia and severe infections in elderly patients, suggesting that it may be considered as an alternative first-line regimen in fit, elderly patients. Long

Full access

Guidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemia

Andrew D. Zelenetz

indicated. Indications for therapy for TLGLL include severe neutropenia (absolute neutrophil count <0.5 x 10 9 /L), moderate neutropenia with recurrent infections, symptomatic or transfusion-dependent anemia, autoimmune disorders associated with TLGLL, and B

Full access

Supportive Care in Head and Neck Cancers: Multidisciplinary Management

Presented by: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber

febrile neutropenia. He received empiric antibiotics and antifungal medications, the neutropenia and fever resolved, and he was discharged. He did not require a nasal gastric tube or a PEG tube during treatment, and he went on to receive adjuvant

Full access

Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presented by: Ann S. LaCasce and Ariela Noy

<.001). 2 The addition of lenalidomide to rituximab was also associated with a trend in improvement in overall survival. “As expected, the combination regimen had higher rates of neutropenia, but infection rates were similar,” she said. “There was also

Full access

Management of Toxicities of BTK Inhibitors in B-Cell Malignancies

Presented by: Muhammad Saad Hamid and Kirollos S. Hanna

cautioned. Dr. Hanna noted that hematologic adverse effects can be profound with drugs such as ibrutinib and zanubrutinib, with up to 25% to 30% of patients experiencing grade 3/4 neutropenia. When using these drugs, clinicians should consider infection

Full access

Treatment Updates in Acute Myeloid Leukemia

Presented by: Alexander E. Perl

- or poor-risk cytogenetics. 6 Every drug has adverse effects, and oral azacitidine carries the risk of significant gastrointestinal toxicity, for which preemptive antiemetics are recommended. Neutropenia is common, but can be managed with dose

Full access

Treatment of Non–Small Cell Lung Cancer in the Older Patient

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

concurrent chemotherapy and radiation. They found that although acute toxicities (esophagitis and neutropenia) were higher in older patients, no differences were seen in long-term toxicity or overall survival based on age. In a similar analysis, Schild et al

Full access

Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis . Cancer Res 2000 ; 60 : 6921 – 6926 . 26 Innocenti F Undevia SD Iyer L . UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan

Full access

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, and Hema Sundar

was also active in patients with Richter's transformation (n=30), resulting in an ORR of 43% (27% CR), and the 1-year OS rate was 28%. 30 However, it was associated with significant toxicity (grade 3 neutropenia was the most common hematologic

Full access

Trends in Recommendations for Myelosuppressive Chemotherapy for the Treatment of Solid Tumors

Robert E. Smith Jr.

first-line treatment in advanced colorectal cancer . J Clin Oncol 2000 ; 18 : 2938 – 2947 . 67. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients